Healthcare / BiotechnologyTaiwan
$44.00
+1.85 (+4.39%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-1.3B · quality 80.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
15/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$13.3B
P/E
N/A
•EV/EBITDA
N/A
•ROE
-9.1%
↓Gross Margin
19.3%
↓Debt/Equity
0.20
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-12.1%
FCF CAGR
—
FCF margin
-131.7%
FCF / Net income
1.74x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $1.01B · net income $-760.6M · FCF $-1.32B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.01B | $1.01B | $1.01B | $1.02B | $1.48B |
| Net Income | $-760.6M | $-760.6M | $-698.3M | $-915.2M | $-115.5M |
| EBITDA | $-505.5M | $-505.5M | $-388.5M | $-664.4M | $100.6M |
| EPS | — | — | -2.28 | -3.00 | -0.38 |
| Gross Margin | 19.3% | 19.3% | 21.7% | 23.1% | 51.1% |
| Operating Margin | -83.9% | -83.9% | -85.8% | -100.9% | -22.4% |
| Net Margin | -75.7% | -75.7% | -69.2% | -89.5% | -7.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.20 | 0.20 | 0.10 | 0.05 | 0.04 |
| Current Ratio | 4.60 | 4.60 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-1.32B | $-1.32B | $-1.24B | $-1.58B | $-935.9M |
| Returns | |||||
| ROE | -9.1% | -9.1% | -7.5% | -9.1% | -1.1% |
| Valuation | |||||
| EV/EBITDA | — | — | — | — | 296.33 |
| P/B | 1.60 | 1.60 | 2.41 | 3.07 | 3.32 |
| Growth & Yield | |||||
| Revenue Growth | -0.4% | -0.4% | -1.3% | -30.9% | — |
| EPS Growth | — | — | 24.0% | -689.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-33.2%
Start / end P/E
n/dx → n/dx
EPS bridge
-2.28 → n/d
Residual
-33.2%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.